New Delhi: In a major relief to Mankind Pharma Limited, the Delhi High Court has directed the removal of the trademark KINDPAN from the Register of Trade Marks, holding that it infringed upon the well ...

If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 12.5%, if your total long term capital gain exceeds 1.25 lakh. Any cess/surcharge is not ...

If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 12.5%, if your total long term capital gain exceeds 1.25 lakh. Any cess/surcharge is not ...

Mankind Pharma has successfully amalgamated its three subsidiaries, namely, Shree Jee Laboratory Pvt. Ltd., JPR Labs Pvt. Ltd. and Jaspack Industries Pvt. Ltd into the company. The merger took ...

Mankind Pharma has officially completed the amalgamation of three of its subsidiaries—Shree Jee Laboratory Private Limited, JPR Labs Private Limited, and Jaspack Industries Private Limited—into the ...

Mankind Pharma has received tax demand orders from the Income Tax Department for Assessment Years (AY) 2014-15 to 2017-18, amounting to ₹183.11 crore, including interest. The demand arises from the ...

Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 ...

Here’s an interesting stock idea: The stock that we have today is Mankind Pharma.The downtrend, which began in the beginning of this year, was arrested by a support last week. The stock ...

Mankind Pharma Limited was incorporated on July 3, 1991, as a Private Limited Company with the name Mankind Pharma Private Limited, by the Registrar of Companies, Delhi and Haryana, at New Delhi.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on AAPG: Disclaimer & Disclosure Report an Issue Ascentage Pharma Group International Unsponsered American Depository Share NewsMORE ...

JPMorgan analyst Yang Huang initiated coverage of Ascentage Pharma (AAPG) with an Overweight rating and HK$52 price target The company’s Olverembatinib, having been approved for three CML ...